pyrimethamine has been researched along with Day Blindness in 9 studies
Maloprim: contains above 2 cpds
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized double-blind study was performed to compare the side effects of long-term chemoprophylaxis of malaria with Fansidar (1 tablet a week) with those of a 300-mg weekly chloroquine regimen." | 5.05 | Tolerability of long-term prophylaxis with fansidar: a randomized double-blind study in Nigeria. ( Leimer, R; Stemberger, H; Wiedermann, G, 1984) |
| "The overall functional prognosis of congenital toxoplasmosis is better than would be expected on the basis of literature findings, with only 2 of the 130 children suffering bilateral visual impairment." | 1.33 | Ocular manifestations in congenital toxoplasmosis. ( Binquet, C; Denis, P; Fleury, J; Garweg, JG; Kodjikian, L; Peyron, F; Wallon, M, 2006) |
| "Many children with congenital toxoplasmosis have substantial retinal damage at birth and consequent loss of vision." | 1.30 | Eye manifestations of congenital toxoplasmosis. ( Boyer, KM; Holfels, E; Hopkins, J; Luciano, R; Mack, D; McLeod, R; Meier, P; Mets, MB; Patel, D; Remington, JS; Roizen, N; Stein, L; Stein, M; Swisher, CN; Withers, S, 1997) |
| "Seventeen of 18 children without hydrocephalus and six of eight children with obstructive hydrocephalus responsive to shunting had normal or near-normal neurologic and developmental outcomes." | 1.29 | Neurologic and developmental outcome in treated congenital toxoplasmosis. ( Boyer, KM; Holfels, E; Hopkins, J; Meier, P; Mets, MB; Patel, D; Roizen, N; Stein, L; Stein, MA; Swisher, CN, 1995) |
| "Many children with congenital toxoplasmosis have substantial retinal damage at birth and consequent loss of vision." | 1.29 | Eye manifestations of congenital toxoplasmosis. ( Boyer, KM; Holfels, E; Hopkins, J; Luciano, R; Mack, D; McLeod, R; Meier, P; Mets, MB; Patel, D; Remington, JS; Roizen, N; Stein, L; Stein, M; Swisher, CN; Withers, S, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, PK | 1 |
| Jianping, C | 1 |
| Vasconcelos-Santos, DV | 1 |
| Arruda, JSD | 1 |
| Dutta Majumder, P | 1 |
| Anthony, E | 1 |
| Ganesh, SK | 1 |
| Biswas, J | 1 |
| Ling, HS | 1 |
| Teoh, SC | 1 |
| Agrawal, R | 1 |
| Furtado, JM | 1 |
| Toscano, M | 1 |
| Castro, V | 1 |
| Rodrigues, MW | 1 |
| Kodjikian, L | 1 |
| Wallon, M | 1 |
| Fleury, J | 1 |
| Denis, P | 1 |
| Binquet, C | 1 |
| Peyron, F | 1 |
| Garweg, JG | 1 |
| Stemberger, H | 1 |
| Leimer, R | 1 |
| Wiedermann, G | 1 |
| Roizen, N | 3 |
| Swisher, CN | 3 |
| Stein, MA | 1 |
| Hopkins, J | 3 |
| Boyer, KM | 3 |
| Holfels, E | 3 |
| Mets, MB | 3 |
| Stein, L | 3 |
| Patel, D | 3 |
| Meier, P | 3 |
| Wei, ME | 1 |
| Campbell, SH | 1 |
| Taylor, C | 1 |
| Stein, M | 2 |
| Withers, S | 2 |
| Mack, D | 2 |
| Luciano, R | 2 |
| Remington, JS | 2 |
| McLeod, R | 2 |
| Dralands, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis[NCT02843438] | 72 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pyrimethamine and Day Blindness
| Article | Year |
|---|---|
Tolerability of long-term prophylaxis with fansidar: a randomized double-blind study in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Blood Cell Count; Chloroquine; Clinical Trials as Topic; Double-Bl | 1984 |
8 other studies available for pyrimethamine and Day Blindness
| Article | Year |
|---|---|
Ocular Toxoplasmosis in Tropical Areas: Analysis and Outcome of 190 Patients from a Multicenter Collaborative Study.
Topics: Adolescent; Adult; Aged; Antibodies, Protozoan; Antiprotozoal Agents; Child; Child, Preschool; Femal | 2018 |
Roth Spots in Ocular Toxoplasmosis.
Topics: Antiprotozoal Agents; Chorioretinitis; Diagnosis, Differential; Drug Therapy, Combination; Humans; I | 2016 |
Ocular manifestations in congenital toxoplasmosis.
Topics: Adolescent; Adult; Antibodies, Protozoan; Antiprotozoal Agents; Child; Child, Preschool; Chorioretin | 2006 |
Neurologic and developmental outcome in treated congenital toxoplasmosis.
Topics: Child Development; Female; Humans; Hydrocephalus; Infant; Infant, Newborn; Intelligence; Longitudina | 1995 |
Precipitous visual loss secondary to optic nerve toxoplasmosis as an unusual presentation of AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Drug Therap | 1996 |
Eye manifestations of congenital toxoplasmosis.
Topics: Adolescent; Adult; Anti-Infective Agents; Child; Child, Preschool; Drug Therapy, Combination; Female | 1996 |
Eye manifestations of congenital toxoplasmosis.
Topics: Adolescent; Adult; Anti-Infective Agents; Child; Child, Preschool; Choroid Diseases; Cicatrix; Femal | 1997 |
[Harmful effects of common drugs on the visual apparatus. Anti-infective drugs. D. Antiprotozoal agents].
Topics: Amidines; Antiprotozoal Agents; Blindness; Eye Diseases; Humans; Metronidazole; Papilledema; Photose | 1972 |